Alpa Laboratories Ltd's Q3FY25 Quarter Results
- 14 Feb 2025
Result Summary
- Alpa Laboratories Ltd reported a 9.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 13.3%.
- Its expenses for the quarter were up by 17.3% QoQ and 1.9% YoY.
- The net profit increased 15.7% QoQ and increased 97.3% YoY.
- The earnings per share (EPS) of Alpa Laboratories Ltd stood at 4.2 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 34.95 | 31.85 | 30.84 | 9.7% | 13.3% |
Total Expenses | 26.05 | 22.20 | 25.56 | 17.3% | 1.9% |
Profit Before Tax | 8.90 | 9.65 | 5.30 | -7.8% | 67.9% |
Tax | 0.00 | 1.96 | 0.79 | -100.0% | -100.0% |
Profit After Tax | 8.90 | 7.69 | 4.51 | 15.7% | 97.3% |
Earnings Per Share | 4.20 | 3.70 | 2.20 | 13.5% | 90.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Alpa Laboratories Ltd is a company engaged in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company produces a variety of formulations in the form of tablets, capsules, injectables, and syrups. It serves both domestic and international markets, leveraging its expertise in developing generics and specialty pharmaceuticals. As of the latest updates, there are no specific major developments mentioned in the data provided for the current quarter.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Alpa Laboratories Ltd reported a total income of ₹34.95 crores. This marks a growth of 9.7% quarter-over-quarter (QoQ) from ₹31.85 crores in Q2FY25 and a year-over-year (YoY) increase of 13.3% from ₹30.84 crores in Q3FY24. The upward trend in total income indicates an increase in sales or revenue generation for the company compared to previous periods. The company's ability to generate higher income over the quarters suggests a potentially expanding market presence or enhanced product performance, although no specific details are provided regarding the product lines contributing to this growth.
Profitability
Alpa Laboratories Ltd's profitability for Q3FY25 is reflected in its Profit After Tax (PAT) of ₹8.90 crores, which represents a QoQ increase of 15.7% from ₹7.69 crores in Q2FY25 and a significant YoY increase of 97.3% from ₹4.51 crores in Q3FY24. The Earnings Per Share (EPS) in Q3FY25 stands at ₹4.20, showing a QoQ rise of 13.5% and a YoY growth of 90.9%. The Profit Before Tax (PBT) for the quarter is ₹8.90 crores, down 7.8% from the previous quarter but up 67.9% from the same quarter last year. Notably, the tax expense for Q3FY25 is reported as zero, contrasting with the previous quarter and the same quarter last year, which recorded tax expenses of ₹1.96 crores and ₹0.79 crores, respectively.
Operating Metrics
The total expenses for Alpa Laboratories in Q3FY25 amounted to ₹26.05 crores, reflecting a QoQ increase of 17.3% from ₹22.20 crores in Q2FY25 and a slight YoY increase of 1.9% from ₹25.56 crores in Q3FY24. This increase in expenses could be attributed to higher operational costs, production expenses, or increased investment in business activities. Despite the rise in expenses, the company has managed to maintain a positive PAT growth due to the substantial increase in total income and the absence of tax expenses in this quarter. The financial data does not provide specific details on other operating metrics such as the debt-to-equity ratio, current ratio, or any other financial ratios.
